LONDON, Sept. 23, 2010-The European Medicines Agency today recommended the suspension of the marketing authorisations for the rosiglitazone-containing anti-diabetes medicines Avandia, Avandamet and Avaglim.
European medicines Agency recommends suspension of Avandia, Avandamet and Avaglim